Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

PF-07826390 is under development for the treatment of solid tumors including non-small cell lung cancer, colorectal cancer and renal cell carcinoma. It acts by targeting leukocyte immunoglobulin like ...

Donald Trump’s allies have raised over $200 million to fund his inauguration, political operations, and presidential library.

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will be paying its dividend of $0.43 on the 7th of ...

Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan ...